Sino Biopharmaceutical Expands Portfolio, Acquires LaNova Medicines for Up to $951M.

Sino Biopharmaceutical has dosed the first patient in a tumor drug study in China. The company's subsidiary will acquire LaNova Medicines for up to $951 million. Sino Biopharmaceutical has also received approval to market its hemophilia drug in China and its tumor drug for first-line treatment of soft tissue sarcoma. The company's breast cancer drug has been included in China's breakthrough therapy designation process.

Sino Biopharmaceutical, a prominent investment holding company in the Chinese pharmaceutical sector, has announced its intention to acquire LaNova Medicines in a deal worth up to $950.9 million. The acquisition, which involves purchasing the remaining 95.09% stake in LaNova that Sino Biopharm does not already own, is set to close within 30 business days after regulatory conditions are met [3].

LaNova, founded in 2019, specializes in the discovery and development of antibody-based cancer treatments. The company has built a robust pipeline, including eight clinical-stage compounds, with notable collaborations with Merck & Co. and AstraZeneca. LaNova's emergence reflects the rapid growth of China's biotech sector, which has evolved from a copycat hub to a global innovator [1].

The acquisition is part of Sino Biopharmaceutical's strategy to expand its oncology portfolio. LaNova's pipeline includes promising compounds such as an antibody-drug conjugate targeting GPRC5D for multiple myeloma and a bispecific antibody targeting PD-1 and VEGF for lung cancer. These drugs align with Sino Biopharm's focus on innovative cancer treatments [1].

Sino Biopharmaceutical has also made significant strides in its own clinical trials and regulatory approvals. The company has dosed the first patient in a tumor drug study in China and received approval to market its hemophilia drug in the country. Additionally, its tumor drug for first-line treatment of soft tissue sarcoma has been granted approval, and its breast cancer drug has been included in China's breakthrough therapy designation process [1].

This acquisition and the company's recent regulatory successes underscore Sino Biopharmaceutical's commitment to innovation and growth in the biopharmaceutical sector. The deal is expected to enhance Sino Biopharmaceutical's competitive position in the global oncology market and further its strategic objectives.

References:
[1] https://www.biopharmadive.com/news/lanova-sino-biopharm-acquisition-china-cancer-drug/753051/
[2] https://finance.yahoo.com/quote/1177.HK/
[3] https://www.reuters.com/business/healthcare-pharmaceuticals/sino-biopharmaceutical-acquire-lanova-medicines-up-951-million-2025-07-15/